Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Polycythemia Vera × peginterferon alfa-2b × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Polycythemia Vera 1 Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

ruxolitinib 15 givinostat hydrochloride 5 givinostat 5 Hydroxyurea 5 Phlebotomy 3 Aspirin 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 bomedemstat 2 LY2784544 2 spartalizumab 1 sonidegib 1 sabatolimab 1 pomalidomide 1 pelcitoclax 1 peginterferon alfa-2b 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 navitoclax 1 lestaurtinib 1 itacitinib 1 imetelstat 1 anagrelide 1 RG7388 1 Pipobroman 1 Panobinostat 1 ON 01910 1 NIS-793 1 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1 Lenalidomide 1 INCB039110 1 Fentanyl 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01949805 2016-11-28

PROUD-PV

AOP Orphan Pharmaceuticals AG

Phase 3 Completed

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon ⚡